A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Abroad (travel likely)RecruitingPHASE3
Conditions
Pneumococcal Infections · Streptococcal Infections · Bacterial Infections
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Contact: Study coordinator (Supattra Rungmaitree, Asst. Prof.)King Chulalongkorn Memorial Hospital, Bangkok, Thailand
Contact: Study coordinator (Thanyawee Puthanakit, Prof.)Phramongkutklao Hospital, Bangkok, Thailand
Contact: Study coordinator (Detchvijitr Suwanpakdee, Col. Asst. Prof.)
Study leads
Supattra Rungmaitree, Doctor of Medicine
Principal Investigator
Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University